Open Orphan PLC Contract extension with Carna Biosciences (4290N)
February 01 2021 - 2:00AM
UK Regulatory
TIDMORPH
RNS Number : 4290N
Open Orphan PLC
01 February 2021
Open Orphan plc
("Open Orphan" or the "Company")
Contract extension with Carna Biosciences
Open Orphan plc (AIM: ORPH), a rapidly growing specialist
pharmaceutical services clinical research organisation (CRO) and a
world leader in vaccine and antiviral testing using human challenge
clinical trials, announces a further contract renewal with Carna
Biosciences, Inc. ("Carna"), extending its integrated drug
development consultancy services with Venn Life Sciences ("Venn"),
part of Open Orphan plc .
Carna Biosciences is a clinical-stage biopharmaceutical company
which focuses on the discovery and development of innovative
therapies to treat serious unmet medical needs, focusing on small
molecule drugs. The renewal of this contract is expected to deliver
significant revenue for Venn over the next twelve months.
The Venn team in the Breda office in the Netherlands, will
provide Chemistry, Manufacturing & Control (CMC), Non-Clinical,
Clinical and Regulatory consultancy services to this client for two
of the client's leading development programmes. This successful
collaboration has been extended until the end of December 2021.
Cathal Friel, Executive Chairman of Open Orphan, said: "The
extension of this contract further demonstrates our ability to
collaborate successfully with our clients and provide a service
that results in repeat business. Venn and Carna have built up a
good working relationship over a period of s everal years where
both parties closely collaborated on drug development planning and
its execution through consultancy services contracts. We look
forward to delivering this contract for Carna in the year
ahead."
Masaaki Sawa, Ph.D., Chief Scientific Officer and Head of
Research and Development at Carna Biosciences, said: "The
partnership with Venn Life Sciences complements our clinical
development team and underlines our commitment to become a clinical
stage company. By continuing the collaboration with the Venn team,
we will accelerate our drug development."
For further information please contact:
Open Orphan plc +353 (0) 1 644 0007
Cathal Friel, Executive Chairman
Arden Partners plc (Nominated Adviser
and Joint Broker) +44 (0) 20 7614 5900
John Llewellyn-Lloyd / Benjamin Cryer
/ Dan Gee-Summons
finnCap plc (Joint Broker) +44 (0) 20 7220 0500
Geoff Nash / James Thompson/ Richard
Chambers
Davy (Euronext Growth Adviser and Joint
Broker) +353 (0) 1 679 6363
Anthony Farrell
Walbrook PR (Financial PR & +44 (0)20 7933 8780 or openorphan@walbrookpr.com
IR)
+44 (0)7876 741 001 / +44
Anna Dunphy / Paul McManus (0)7980 541 893
Notes to Editors
About Carna Biosciences, Inc. ( www.carnabio.com/english)
Carna Biosciences is a clinical-stage biopharmaceutical company
founded in April 2003 in Kobe, Japan to discover and develop
innovative therapies to treat serious unmet medical needs, focusing
on small molecule drugs, mainly targeting kinases. We also offer a
broad range of high-quality products and innovative drug discovery
services to scientists worldwide to help efficiently identify new
kinase inhibitors.
About Open Orphan plc ( www.openorphan.com )
Open Orphan is a rapidly growing niche CRO pharmaceutical
services company which is a world leader in the testing of vaccines
and antivirals through the use of human challenge clinical trials.
Conducted from Europe's only 24-bedroom quarantine clinic with
onsite virology providing individually isolated rooms and connected
to our specialist laboratory facility. hVIVO's challenge studies
require healthy volunteers to take part, volunteers are recruited
through FluCamp, learn more at www.FluCamp.com . The hVIVO facility
offers highly specialised virology and immunology laboratory
services to support pre-clinical and clinical respiratory drug,
antiviral, and vaccine discovery and development. Reliable
laboratory analysis underpinned by scientific expertise is
essential when processing and analysing clinical samples. Robust
quality processes support our team of scientists in the delivery of
submission ready data.
The Company has a leading portfolio of 8 viral challenge study
models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough and 1 COPD
viral challenge models. As announced in early March, Open Orphan is
rapidly advancing a number of Coronavirus challenge study models
and expects to be helping many COVID-19 vaccine development
companies to test their vaccines. No other company in the world has
such a portfolio, with only two competitors globally having 1
challenge study model each. hVIVO also works with companies in the
UK and Ireland to provide COVID-19 testing to staff to protect
staff and customers from a workplace COVID-19 outbreak through its
COVID Clear offering.
Open Orphan comprises of two commercial specialist CRO services
businesses, hVIVO and Venn Life Sciences and is also building out a
valuable data platform business. hVIVO has built up one of the
world's largest databases of infectious disease progression data
and we are populating our Open Orphan Health Data platform with
this historical hVIVO data. In our clinical trials going forward,
we are also planning to collect data on volunteers via wearables
during clinical trials. Therefore, Open Orphan's data, which may
yield valuable digital biomarkers, could be one of the more
sought-after datasets by many of the large wearables /smart watch
wearables providers around the world. In June 2019, Open Orphan
acquired AIM-listed Venn Life Sciences Holdings plc in a reverse
take-over and in January 2020 it completed the merger with hVIVO
plc. Venn is an integrated drug development consultancy firm which
offers CMC (chemistry, manufacturing and controls), preclinical,
Phase I & II clinical trials design and execution. The merger
with hVIVO created a European full pharma services company
broadening the Company's customer base and with complementary
specialist CRO services, widened the range of the Company's service
offerings.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTBLGDBIBDDGBC
(END) Dow Jones Newswires
February 01, 2021 02:00 ET (07:00 GMT)
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Jul 2023 to Jul 2024